Novo Nordisk and Eli Lilly are offering discounts to encourage more insurance coverage of the medicines, which carry price tags of over $1,000 a month.

Weight-loss drugs like Ozempic are booming in popularity, but experts warn they aren't silver bullets for obesity.

One of the researchers described the circumstances that led to the discovery as “serendipity.” This year’s prestigious Lasker medical awards recognize a trio of scientists without whom Ozempic and other blockbuster weight-loss drugs might not exist.

F ROM LOS ANGELES to London, weight-loss drugs such as Ozempic are reshaping culture as much as waistlines. Some Ozempic-takers have tiny appetites and dine at unusual hours to avoid spells of nausea.

Many people are doing an end-run around their doctor's office, reaching out to potentially unreliable sources that promise to set them up with Wegovy, Zepbound and other weight-loss drugs.

Half a century of advancements in biomedical science paved the way for today's powerful weight-loss drugs like Ozempic -- so what was that journey like for the scientists involved?

Research has shown there are plenty of perks of using a medication like Ozempic for weight loss. But, given that this is a drug, there are some potential downsides to consider, too. New research published in JAMA Network Open links GLP-1 receptor agonists—a class of medications that includes semaglutide medications like Ozempic and Wegovy—to a loss of bone density.